About ADVANZ PHARMA
ADVANZ PHARMA is a Healthcare company based in Vancouver (Canada) founded in 1986, and was acquired by Advanz Pharmaceutical in March 2020. ADVANZ PHARMA is engaged in providing specialty and rare disease medicines. It operates on a Direct-to-Consumer (D2C) and B2B2C model. ADVANZ PHARMA has raised $40 million across 5 funding rounds from investors including Advanz Pharmaceutical, Allergan and Cardiome. ADVANZ PHARMA offers products and services including Specialty Medicines, Biosimilars, and Generics. Its focus areas include Pharmaceuticals, Specialty Pharmaceuticals, Biotechnology and Biosimilars. Its legal entity is ADVANZ PHARMA Corp. Limited.
Company details
ADVANZ PHARMA is focused on the commercialization of specialty, hospital, and rare disease medicines. Operations are conducted globally, with a presence in over 90 countries, covering therapeutic areas such as hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and oncology. A diverse portfolio of innovative medicines, specialty generics, biosimilars, and originator brands is maintained. Partnerships with over 300 entities in production, development, and licensing are established to broaden patient access. Efforts are made to enhance patient care and lower healthcare costs through a growing biosimilars portfolio. The company is headquartered in London, UK, with additional centers of excellence and offices worldwide.
- Headquarters Vancouver, Canada
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website correvio.com
- Social LinkedIn
- Acquired by Advanz Pharmaceutical (Mar 2020)
- Legal Name Advanz Pharma Corp. Limited
- Total Equity Funding$40M (USD)
in 5 rounds
- Latest Funding Round$10M (USD), Debt – Conventional
Mar 2019
- InvestorsAdvanz Pharmaceutical
& 3 more
- Acquired by
Products & Services of ADVANZ PHARMA
ADVANZ PHARMA offers a comprehensive portfolio of products and services, including Specialty Medicines, Biosimilars, and Generics.
Specialty medicines are provided for various therapeutic areas.
Biosimilars are developed to expand treatment options affordably.
Generic medicines are offered for cost-effective patient care.
Funding Insights of ADVANZ PHARMA
ADVANZ PHARMA has successfully raised a total of $40M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $10 million completed in March 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 5
- Last Round Debt – Conventional — $10M
- First Round $27M
(Feb 2014)
- Investors Count 2
All 5 funding rounds of ADVANZ PHARMA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
4 investors in total: 4 institutional.
Investors in ADVANZ PHARMA
ADVANZ PHARMA has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Advanz Pharmaceutical, Allergan and Cardiome.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States | |
Specialty generic and off-patent medicines are manufactured in various forms. | 1963 | advanzpharma.com | Mississauga, Canada | |
Therapies for heart and circulatory disorders are developed and commercialized. | 1990 | cardiome.com | Vancouver, Canada |
Investor details for ADVANZ PHARMA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ADVANZ PHARMA
12 people are tracked at ADVANZ PHARMA (4 in leadership, 6 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
David Dean | Chief BDO | Leadership |
Sheila Grant | COO | Leadership |
Mark H. Corrigan | CEO | Leadership |
Justin A. Renz | President and CFO | Leadership |
Arthur H. Willms | Board Member | Board & advisors |
James O’Shea | Chair | Board & advisors |
Vanda De Cian | Board Member | Board & advisors |
Richard M. Glickman | Board Member | Board & advisors |
Robert James Meyer | Board Member | Board & advisors |
William Hunter | Board Member | Board & advisors |
Hugues Sachot | CCO | Team |
David Mcmasters | General Counsel | Team |
Complete people profiles for ADVANZ PHARMA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ADVANZ PHARMA
6 dated milestones of ADVANZ PHARMA across 34 years, from founding to its latest funding, stage changes and deals.
- Founded ADVANZ PHARMA is founded.
- Exit Acquired by Cardiome.
- Funding First funding round of $27.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $10.0M.
- Exit Acquired by Advanz Pharmaceutical.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ADVANZ PHARMA
ADVANZ PHARMA was founded in 1986 and raised its 1st funding round 28 years after it was founded.
ADVANZ PHARMA is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
ADVANZ PHARMA is a funded company, having raised a total of $40M across 5 funding rounds to date. The company's 1st funding round was a Series B of $27M, raised on Feb 2014.
ADVANZ PHARMA is focused on the commercialization of specialty, hospital, and rare disease medicines. Operations are conducted globally, with a presence in over 90 countries, covering therapeutic areas such as hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and oncology. A diverse portfolio of innovative medicines, specialty generics, biosimilars, and originator brands is maintained. Partnerships with over 300 entities in production, development, and licensing are established to broaden patient access. Efforts are made to enhance patient care and lower healthcare costs through a growing biosimilars portfolio. The company is headquartered in London, UK, with additional centers of excellence and offices worldwide.
ADVANZ PHARMA offers Specialty Medicines, Biosimilars, and Generics.
ADVANZ PHARMA has 4 investors. Key investors include Advanz Pharmaceutical, Allergan, Cardiome, and CRG.
ADVANZ PHARMA operates through Advanz Pharma Corp. Limited.
Yes. ADVANZ PHARMA was acquired by Advanz Pharmaceutical in March 2020.